Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
- PMID: 16823932
- DOI: 10.1016/j.vaccine.2005.01.126
Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
Abstract
Staphylococcus aureus is a ubiquitous bacterial species that causes serious disease in certain settings. S. aureus disease is difficult to treat, and antibiotic-resistant strains have become common. A vaccine to protect against infection would therefore be beneficial. However, the virulence of S. aureus is determined by a number of different factors, which makes design of a widely effective vaccine difficult. Here, various bacterial virulence factors and attempts to develop vaccines based on these factors are briefly reviewed. In particular, the success of a Phase 3 clinical study of a vaccine directed at capsular polysaccharides types 5 and 8 is discussed.
Similar articles
-
Prevention of Staphylococcus aureus infections: advances in vaccine development.Expert Rev Vaccines. 2005 Oct;4(5):669-76. doi: 10.1586/14760584.4.5.669. Expert Rev Vaccines. 2005. PMID: 16221068 Review.
-
O-Acetylation is essential for functional antibody generation against Staphylococcus aureus capsular polysaccharide.Hum Vaccin Immunother. 2018 Jan 2;14(1):81-84. doi: 10.1080/21645515.2017.1386360. Epub 2017 Dec 11. Hum Vaccin Immunother. 2018. PMID: 29182428 Free PMC article.
-
Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.Hum Vaccin Immunother. 2017 Jul 3;13(7):1609-1614. doi: 10.1080/21645515.2017.1304334. Epub 2017 Apr 19. Hum Vaccin Immunother. 2017. PMID: 28422567 Free PMC article.
-
Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.Infect Immun. 2014 Jan;82(1):83-91. doi: 10.1128/IAI.01050-13. Epub 2013 Oct 14. Infect Immun. 2014. PMID: 24126523 Free PMC article.
-
Vaccination and passive immunisation against Staphylococcus aureus.Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S71-8. doi: 10.1016/j.ijantimicag.2008.06.009. Epub 2008 Aug 30. Int J Antimicrob Agents. 2008. PMID: 18757184 Review.
Cited by
-
Will there ever be a universal Staphylococcus aureus vaccine?Hum Vaccin Immunother. 2013 Sep;9(9):1865-76. doi: 10.4161/hv.25182. Epub 2013 Jun 21. Hum Vaccin Immunother. 2013. PMID: 23793522 Free PMC article.
-
Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.Infect Immun. 2008 Dec;76(12):5738-44. doi: 10.1128/IAI.00874-08. Epub 2008 Sep 22. Infect Immun. 2008. PMID: 18809660 Free PMC article.
-
Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.Front Immunol. 2014 Jan 8;4:507. doi: 10.3389/fimmu.2013.00507. Front Immunol. 2014. PMID: 24409186 Free PMC article. Review.
-
Safety of Staphylococcus aureus four-antigen and three-antigen vaccines in healthy adults: A meta-analysis of randomized controlled trials.Hum Vaccin Immunother. 2018 Feb 1;14(2):314-321. doi: 10.1080/21645515.2017.1395540. Epub 2017 Dec 6. Hum Vaccin Immunother. 2018. PMID: 29064736 Free PMC article.
-
The potential economic value of a Staphylococcus aureus vaccine for neonates.Vaccine. 2010 Jun 23;28(29):4653-60. doi: 10.1016/j.vaccine.2010.04.069. Epub 2010 May 14. Vaccine. 2010. PMID: 20472028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical